Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
Traws Pharma Announces Management Updates
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Traws Pharma stock soars 200% on encouraging bird flu drug data
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights